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ABSTRACT
Aim: To compare between entecavir and lamivudine as hepatitis B reactivation prophylaxis in cancer patient 
with chemotherapy
Method: A literature searching in PubMed was done. At the beginning, 8 articles were found. Chosen article in 
this EBCR were those which compared lamivudine and entecavir directly to lymphoma patient in chemotherapy. 
Six articles were excluded. Besides PubMed, literature searching was done in Highwire, Cochrane, and Google 
Scholar too. In Google Scholar, one article that compared entecavir and lamivudine as hepatitis B prophylaxis in 
cancer patient was found in this study, there were also two multicenter retrospective study that will be appraised. 
Results: Hepatitis B virus (HBV) reactivation, HBV related hepatitis, and chemotherapy discontinuity as a 
consequence of Hepatitis B were found to be lower in entecavir groups. Entecavir was more effective in subjects 
with measured HBV deoxyribonucleic acid (DNA). In unmeasured HBV DNA groups, entecavir were as effective 
as lamivudine.
Conclusion: Entecavir were found to be more effective than lamivudine in patient with positive HBsAg or 
advanced stage of malignancy that were prepared for aggressive chemotherapy regiments. Since entecavir cost 
was unaffordable, lamivudine still a drug of choice in this situation. 
Keywords: entecavir, lamivudine, prophylaxis hepatitis B reactivation, chemotherapy
ABSTRAK
Tujuan: 0HQJHWDKXLPHQJHQDLSHUEDQGLQJDQHQWHFDYLUGDQODPLYXGLQHVHEDJDLSUR¿ODNVLVUHDNWLYDVLKHSDWLWLV
B pada pasien keganasan dalam kemoterapi.
Metode: Dilakukan pencarian literatur di PubMed. Dari pencarian awal di Pubmed, diperoleh 8 artikel. 
Artikel yang terpilih dalam EBCR ini adalah studi yang membandingkan lamivudine dan entecavir secara 
langsung pada pasien limfoma dalam kemoterapi. Sejumlah 6 artikel dieksklusi. Selain Pubmed dilakukan juga 
pencarian artikel di Highwire, Cochrane dan Google Scholar. Pada Google Scholar ditemukan satu artikel yang 
PHPEDQGLQJNDQHQWHFDYLUGDQODPLYXGLQHVHEDJDLSUR¿ODNVLVKHSDWLWLV%SDGDSDVLHQNHJDQDVDQ3DGDODSRUDQ
ini, terdapat dua studi multisenter retrospektif yang akan dilakukan telaah lebih lanjut.
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Hasil: Angka reaktivasi hepatitis B virus (HBV), hepatitis terkait HBV dan terputusnya kemoterapi akibat 
hepatitis lebih rendah pada kelompok entecavir. Entecavir lebih efektif pada kelompok subjek dengan kadar 
HBV deoxyribonucleic acid (DNA) terukur. Pada kelompok subjek dengan HBV DNA tidak terukur entecavir 
memiliki efektivitas yang sama dengan lamivudine.
Simpulan: Entecavir lebih efektif dibandingkan lamivudine pada pasien dengan status HBsAg positif ataupun 
pasien yang memiliki keganasan stadium lanjut dan akan menjalani kemoterapi jangka panjang dengan regimen 
yang berat. Akan tetapi karena biaya entecavir yang masih belum terjangkau maka lamivudine masih merupakan 
terapi pilihan pada kasus ini.
Kata kunci: entecavir, lamivudine, SUR¿ODNVLVUHDNWLYDVLKHSDWLWLV%, kemoterapi
could evoke its resistance lead to a question about how 
effective entecavir as a drug of choice in Indonesia 
for HBV reactivation prophylaxis in chemotherapy 
patients. This is the reason why this topic were 
discussed in this evidence-based case report. 
CLINICAL QUESTION
A 45 years old male patient, unemployed, married 
and have 3 child with Gakin health insurance came to 
Hematology Clinic in RSCM recommended to 3rd cycle 
of RICE (rituximab, ifosfamide-carboplatin-etoposide) 
chemotherapy. One year before he came to hospital, 
patient was complaining about a lump in his left neck 
DQGWZRRWKHUOXPSLQKLVD[LOODDVELJDVPDUEOHV¿UP
and immobile. Patient then done a biopsy procedure, 
told to have lymph node malignancy. Six months 
before came into hospital, patient were also undergo 
ultrasonography (USG) procedure, told to have a 
swollen kidney and recommended to implant a DJ 
stent. Patient was also complaining about abdominal 
bloating, and dyspnea during supine position. Fluid 
were found in patient lung and drained during one 
month hospitalization. Patient then underwent a 
cyclophosphamide-hydroxydaunirubicine-oncovin-
prednisone (CHOP) chemotherapy once (5 months 
before hospitalization) with abdominal bloating and 
reduce dyspnea. There was improvement in apetite. 
Patient then continues a three section of chemotherapy 
using CHOP. After the evaluation, disease were 
considered as stable so that chemotherapy could be 
switched into rituximab-ifosfamide-carboplatin-
etoposide (RICE). At present, febrile, night sweat, 
dyspnea, and abdominal bloating were denied by 
patient. Patient were diagnosed hepatitis B from six 
month before hospitalization and given lamivudine 
therapy of 1x100 mg. Patient denied any hepatitis 
history, and also denied diabetes mellitus, hypertension, 
asthma, allergy, and cardiovascular disease history. 
Patient’s child were having a nasopharyngeal 
INTRODUCTION
Hepatitis B infection were one of the risk factors of 
hepatocellular carcinoma (HCC) and reported to infect 
more than 350 million people worldwide. Besides 
interferon therapy, analog nucleoside therapy such 
as lamivudine, adefovir, and entecavir were a new 
promising antiviral to inhibit reverse transcriptase 
enzyme of HBV.1 HBV reactivation could also 
occur during the use of chemotherapy agents or 
immunosuppressive agents.1 It has been reported that 
HBV reactivation were found higher in lymphoma 
malignum, hematologic malignancy, and other 
rheumatologic and oncologic disease.2 HBV reactivation 
risk were proportional to immunosuppressive therapy 
alongside whatever patients hepatitis B surface antigen 
(HBsAg) status.1 Various report showed that HBC 
reactivation were commonly occur in lymphoma 
malignum on combination chemotherapy such as 
rituximab and steroid, with incidence rate 14-72%.1,3 
Koo et al investigated that patients with advanced 
stage disease have a higher risk of HBV reactivation.4 
In those patients, HBV reactivation could lead to 
fulminant hepatitis or even liver failure. Because 
of that, the need of hepatitis B reactivation during 
chemotherapy period with immunosuppressant should 
be further discussed.2
Lamivudine was a nucleoside analog to inhibit 
ribonucleic acid-dependent (RNA-dependent) 
deoxyribose nucleic acid (DNA) polymerase in 
HBV replication cycle, reduce HBV DNA in serum, 
and repair liver tissue damage in HBV infection. 
Lamivudine was well tolerated and safe for chronic 
use. Otherwise, recently a long period use of 
lamivudine were associated with drug-resistant 
tyrosine-methionine-aspartate-aspartate mutation risk.5
Entecavir was a nucleoside analog considered 
potentially better antiviral effect than lamivudine 
with lower resistances in prevent HBV reactivation.6 
Several studies about how chronic use of lamivudine 
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carcinoma. A tattoo were found in patients arm with 
alcoholism history, but denied promiscuity, abuse 
needle use, and any transfusion history. 
During physical examination, patient was compos 
mentis, looks ill, with vital sign considered normal. 
There were no abnormality in eye, neck, lung, and 
heart examination. There were no hepatomegaly 
and splenomegaly. There were no neck, axilla, 
supraclavicular, and inguinal lymph node enlargement. 
Hematologic examination shows an normocytic 
normochromic anemia with Hb 10.2 g/dL, and normal 
transaminase (AST/ALT 23/16). Hepatitis marker 
laboratory examination shown a positive in HbsAg, anti-
+%HDQGWRWDODQWL+%F3DWKRORJLF¿QGLQJVVKRZHG
diffused lymphoma malignum with large cell type and 
moderate malignancy grade. Immunohistochemistry 
examination showed a positive in CD 20, CD 3, CD 5, KI-
67, and bcl-2 with conclusion as lymphoma malignum 
non-Hodgkin, B cell, large, and diffuse from the 
pathologist. Bone marrow biopsy showed a hypercellular 
without metastasis. Thorax plain photograph showed an 
pleural effusion of left lung, but diminished in the next 
month. Echocardiography examination considered 
normal. Abdominal USG showed a liver cirrhosis with 
malignant tendency, bilateral pleural effusion, paraaortic 
lymph node enlargement, and bilateral hydronephrosis. 
CT scan examination revealed an paraaortic lymph node 
enlargement from hepatic hylum into abdominal aorta 
bifurcation with prominent bilateral hydronephrosis. 
After two chemotherapy, CT scan examination showed 
reduce of paraaortic lymph node size and hydronephorsis 
was disappeared, but pleural effusion and a lesion 
in vertebral column Th12-L4 were founded. Pleural 
ÀXLGH[DPLQDWLRQVKRZHGDQQRQ+RGJNLQO\PSKRPD
malignum cell. At present, patient were prepared for the 
third RICE, ranitidine 2x50 mg, ondansetron 3x8 mg, 
curcuma 3x200 mg, and lamivudine 1x100 mg. After 
the third chemotherapy, transaminase were increase 
more than three times AST/ALT 209/197 u/L with 
bilirubin total/direct/indirect account 3.82/2.61/1.22 
mg/dL respectively. 
From the illustration above, the clinical question 
IRU WKLV VLWXDWLRQ GH¿QHG DVZKDW LV WKH EHVW+%9
reactivation prophylaxis therapy for patient with 
malignany in chemotherapy: lamivudine or entecavir?
METHOD
7R¿QGDQDQVZHURIWKHFOLQLFDOTXHVWLRQDERYH
we formulate a PICO table to guide the literature 
searching (Table 1)
7DEOH)RUPXODWLRQRI3,&2TXHVWLRQ
Variable ,GHQWL¿FDWLRQ
Problem
Intervention
Comparison
Outcome
HBV reactivation in lymphoma ongoing a 
chemotherapy 
Entecavir
Lamivudine
No HBV reactivation
A literature searching in PubMed was done 
with keywords: entecavir AND lamivudine 
AND lymphoma chemotherapy.  In detai ls : 
(“ lamivudine”[MeSH Terms] OR “lamivudine”[All 
Fields] AND (“entecavir”[Supplementary Concept] OR 
“entecavir”[All Fields]) AND ((“lymphoma”[MeSH 
Terms] OR “lymphoma”[All Fields]) AND (“drug 
therapy”{Subheading] OR (“drug[All Fields] AND 
“therapy”[All Fileds]) OR “drug therapy”[All 
Fields] OR “chemotherapy”[All Fields] OR “drug 
therapy”[MeSH Terms] OR (“drug”[All Fields] 
AND “therapy”[All Fields]) OR “chemotherapy”[All 
Fields])).
)URPWKH¿UVWOLWHUDWXUHVHDUFKLQJLQ3XE0HGHLJKW
articles were found. Seven from eight were English, 
while the other one written on Chinese language 
were excluded. The seven remaining articles were 
appraised by reading the full tect. The choosen article 
for this EBCR is the one that compared lamivudine 
and entecavir directly in lymphoma patients undergo 
chemotherapy. Six article were excluded as they were 
QRW IXO¿OO WKH UHTXLUHG FULWHULD/LWHUDWXUH VHDUFKLQJ
algorithm can be seen in Figure 1. Besides PubMed, 
literature searching was also done in Highwire, 
Cochrane, and Google Scholar. In Google Scholar 
searching, on article was found which copared 
entecavir and lamivudine as hepatitis B prophylaxis in 
malignancy. Therefore, in this EBCR two multicenter 
studies were appraised in advanced. 
During critical appraisal of those articles, a guide by 
3ROJDU$DQG7KRPDV6$LQµ&ULWLFDO$SSUDLVDO6NLOOV
Programme’ for clinical obsevationa study (cohort, 
case control, cross sectional) was used. 
7KH¿UVWDUWLFOHZHUHIRXQGGXULQJ3XE0HGOLWHUDWXUH
searching. The author of this article was Li HR with 
tittle “Comparison of entecavir and lamivudine in 
preventing hepatitis B reactivation in lymphoma 
patients during chemotherapy” from Journal of Viral 
Hepatitis 2011;18:877 – 883. The second article from 
Google Scholar authored by Chen FW et al with 
tittle “Entecavir versus lamivudine for hepatitis B 
prophylaxis in patients with haematological disease” 
pubished by John Wiley & Sons, can be downloaded 
via doi: 10.1111/liv.125154.2013. Appraisal for both 
article were shown in Table 2. 
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value) and HBV infection in both group (by assessing 
the increase of transaminase). Subject on both study 
was a hepatitis B patient with either positive or 
negative HBsAg but positive anti-HBc. There were 
no differences in characteristic among the two studies. 
In Li HR et al, all subject were lymphoma patient 
with almost having cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) chemotherapy 
agents, while in Chen FW et al, subject were in various 
hematologic malignancy, although most of the subject 
is having lymphoma. Dosage used in both study was 
100 mg lamivudine and 0.5 mg entecavir. 
HBV reactivation defined as the increasing of 
HBV DNA > 1 log10 or the appearance of HBsAg 
in resolution stage of post HBV infected patients. 
HBV reactivation could be accompanied by sign and 
symptoms of hepatitis.8+HSDWLWLVZDVGH¿QHGDV WKH
increasing serum ALT more than three times from 
normal range, or an absolute ALT increase of more 
than 100 U/L from baseline. HBV related hepatitis were 
GH¿QHGDV+%9UHDFWLYDWLRQLQUHODWLRQZLWKKHSDWLWLV
during six months post chemotherapy without any sign 
of acute viral hepatitis or any other systemic infections.3,7
Li HR reported an incidence rate of hepatitis (5.9% 
vs 27%; p = 0.007), stopped chemotherapy cycle 
because of hepatitis (5.9% vs. 20.2%; p = 0.042), and 
7DEHO$UWLFOHDSSUDLVDO
/L+5HWDO

Chen FW et 
DO
What is the paper about?
1. Is the study relevant to the needs of the project?  
2. Does the paper address a clearly focused issue?
 Are the aims of the investigation clearly stated?
Yes
Yes
Yes
Yes
Do I trust it?
+DYHWKHDXWKRUVUHÀHFWHGWKHFXUUHQWVWDWHRINQRZOHGJHDFFRUGLQJWRDQXQELDVHGUHYLHZRIWKH
literature?
 +DVDVXI¿FLHQWO\FRPSOHWHVHDUFKRIWKHUHOHYDQWOLWHUDWXUHEHHQFDUULHGRXW"
 Is the evidence included which is unfavourable to the authors point of view?
4. Is the choice of study method appropriate?
 Is the study aim clearly stated?
5. Is the population studied appripriate?
 Is an appropriate control group used?
6. Is confounding and bias considered?
 Have all possible explanations of the effect been considered??
 Were the assessors blind to the different groups?
 Could selective drop out explain the effect?
7. Was follow up for long enough?
 Could all likely effects have appeared in the time scale?
 Could the effect be transitory?
 :DVIROORZXSVXI¿FLHQWO\FRPSOHWH"
8. Was dose response demonstrated?
Yes
Yes
Yes
Yes
Yes
can’t tell
Yes
Yes
Yes
Yes
Yes
can’t tell
:KDWGLGWKH\¿QG"
9. Are tables/graphs adequately labelled and understandable?
$UH\RXFRQ¿GHQWZLWKWKHDXWKRUVFKRLFHDQGXVHRIVWDWLVWLFDPHWKRGVLIHPSOR\HG"
11. What are the result of this piece of research?
 Are the authors conclusions adequately supported by the information cited?
Yes
Yes
Yes
Can’t tell
Yes
Yes
Are the results relevant locally?
12. Can the result be applied to the local situation?
13. Were all important outcomes/results considered?
14. Accepted for further use as Type IV evidence?
Yes
Yes
Yes
Yes
Yes
Yes
ϭĂƌƚŝĐůĞĞǆĐůƵĚĞĚ
;ŚŝŶĞƐĞůĂŶŐƵĂŐĞͿ
ϲĂƌƚŝĐůĞƐ ĞǆĐůƵĚĞĚ
;ŝƌƌĞůĞǀĂŶƚƚŽƚŽƉŝĐ
ĐŚŽƐĞŶͿ
ϮĂƌƚŝĐůĞƐ ǁĞƌĞ
ĐƌŝƚŝĐĂůůǇĂƉƉƌĂŝƐĞĚ
ϴWƵďDĞĚ
ĂƌƚŝĐůĞƐ
WƵďŵĞĚ
ϭ'ŽŽŐůĞ
^ĐŚŽůĂƌĂƌƚŝĐůĞ
'ŽŽŐůĞ^ĐŚŽůĂƌ
)LJXUH$UWLFOH VHOHFWLRQDOJRULWKP LQ WKLV HYLGHQFHEDVHG
case report
RESULTS
In this evidence-based case report, both article 
found were a retrospective study directly compared 
entecavir and lamivudine as hepatitis B prophylaxis 
in chemotherapy. Outcome of those study was HBV 
reactivation percentage (by assessing HBV DNA 
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HBV related hepatitis (0% vs. 12.4%, p = 0.24) were 
VLJQL¿FDQWO\ORZHULQHQWHFDYLUJURXSV5HDFWLYDWLRQ
of HVB were clinically lower in entecavir group than 
lamivudine group (11.8% vs. 20.2%), but statistically 
LQVLJQL¿FDQWS 3 In the study by Chen et al, 
subject with undetected HBV DNA at the beginning of 
therapy, both entecavir and lamivudine were effectively 
the same.7 Otherwise, in subject with detected HBV 
DNA at the beginning of therapy, entecavir therapy 
showed no hepatitis B reactivation, while one from six 
patient from lamivudine group were having hepatitis B 
UHDFWLYDWLRQ7KLV¿QGLQJVFRXOGH[SODLQWKDWHQWHFDYLU
were more effective than lamivudine. It also can be 
FRQFOXGHGWKDWODPLYXGLQHZHUHVWLOOD¿UVWOLQHWKHUDS\
for hepatitis B prophylaxis in HBsAg negative and 
immune control phase with undetected HBV DNA 
patients. Entecavir should be saved for patients with 
detected HBV DNA (immune tolerant phase, immune 
clearance phase, or eAg negative) because of the lower 
risk of drug resistance. A little number of sample is one 
of the weakness of this study.
Study by Li HR et al conclude that reactivation 
prophylaxis for hepatitis B were based on cancer 
stadium occurred.3 In the early stage cancer or patients 
with short duration chemotherapy, lamivudine still a 
drug of choice for hepatitis B reactivation prophylaxis. 
On the other hand, patients with advanced stage cancer 
or patients required long duration of chemotherapy, 
entecavir should be the drug of choice. Comparison of 
both Li et al and Chen et al study result were shown 
in table 3. 
DISCUSSION
HBV chronic infection were marked as detected 
HBsAg. Chronic HBV infection were having four 
stages: immune tolerant phase, immune clearance 
phase, immune control phase (inactive carrier status), 
and immune escape phase.9 A few recent years 
showed that hepatitis B reactivation were found in 
chemotherapy patients.3 Hepatitis b reactivation 
were a life-threatening complication that infect 
patients with malignancy during chemotherapy.6 In 
immunocompromised patients, resolute HBV could 
be reactivated too. Resolute infection marked as anti-
HBc detected without anti-HBs.7 HBV reactivation 
prevention could reduce mortality of HBV infection 
and could reduce chemotherapy dosage caused by 
HBV reactivation.10
Lamivudine were HBV reactivation prophylaxis that 
recommended in many guidelines. Patients with HBV 
reactivation risk recommended to start antiviral therapy 
a week before chemotherapy, continued to the next 
PRQWKV DIWHU FKHPRWKHUDS\¿QLVKHG11 lamivudine 
were formerly known as the only nucleoside analog 
to treat chronic hepatitis B infection.3 lamivudine act 
as inhibitor of virus replication effectively reduce 
HBV DNA level and reduce hepatic damage due to 
chronic hepatitis B infections.7 The role of lamivudine 
as prophylaxis has been widely proofed in various 
clinical trial and was recommended in many guidelines. 
Otherwise, lamivudine as long term hepatitis therapy 
were restricted as recently found a hepatitis B virus 
that is resistance to lamivudine.3 Long term use of 
lamivudine for hepatitis B was known to cause drug 
resistance and hepatitis exacerbation.12,13 Lamivudine 
was having a higher mutation rate, about 20% in one 
year and increase to 70% in 5-years therapy. In this 
case, hepatitis B reactivation could occur even patient 
have got lamivudine therapy before.3
Entecavir were HBV DNA polymerase inhibitor 
selective that have an ability to inhibit viral replication, 
optimize histologica repair, reduce chronic hepatitis 
B progression, and lower resistance rate rather than 
lamivudine.7 As this reason, entecavir were widely 
used as chronic hepatitis B therapy in Japan, replacing 
lamivudine since 2000.13,14 But, there were few studies 
to investigate its effect as hepatitis B reactivation 
prophylaxis in chemotherapy patients. Previous study 
only investigate entecavir role as therapeutic drugs 
for hepatitis B reactivation in chemotherapy patients. 
Choosing the best prophylaxis therapy for hepatitis 
7DEHO&RPSDULVRQRIVWXG\E\/L+5HWDODQG&KHQ):HWDO
Parameter Li et al Chen et al
Study design Retrospective cross sectional Retrospective cross sectional
Population Patients with lymphoma malignum with positive of either 
HBsAg, HBeAb, HBeAg or antiHBc.
Patients with cancer or other hematologic malignancy with 
either positive or negative HBsAg but positive anti-HBc
Intervention Lamivudine 100 mg, entecavir 0.5 mg Lamivudine 100 mg, entecavir 0.5 mg
Parameter HBV reactivation, HBV related hepatitis, stopped 
chemotherapy because of hepatitis 
HBV reactivation, hepatitis, HBV related hepatitis
Result HBV reactivation rate, HBV related hepatitis, and stopped 
chemotherapy because of hepatitis shown to be lower in 
entecavir group
Entecavir were more effective in detected HBV DNA 
subjects. In undetected HBV DNA subjects, entecavir were 
as effective as lamivudine
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B reactivation could be a problem for hepatologist 
and hematologist. This choice were based on patients 
preference. There were no meta-analysis or systematic 
review found to discuss about lamivudine and entecavir 
as prophylaxis in chemotherapy patients. Recent study 
only a retrospective study and only said that entecavir 
could be used as prophylaxis therapy for hepatitis B 
reactivation during chemotherapy.6,8,15
Critical appraisal on article shown a nearly the same 
effect on chemotherapy patients with formerly resolute 
hepatitis B infection. Entecavir were proofed to be more 
effective in patients with positive HBsAg.7 Patients with 
negative HBsAg and positive anti-HBc were a sign of 
HBV infection resolution. If we apply Chen FW et al 
study result into this case, entecavir were choosen as 
therapy rather than lamivudine.7 Patients in this case is 
a stage IV lymphoma with lung metastasis shoud be 
undergo a long term chemotherapy. Based on Li HR et 
DOHQWHFDYLUZHUHD¿UVWFKRLFHIRUDGYDQFHGPDOLJQDQF\
so that this patients should get an entecavir therapy as 
hepatitis B reactivation prophylaxis.3 But, there were not 
enough evidence yet to support that conclusion. Study 
which compared entecavir and lamivudine effectiveness 
in chemotherapy patients were found in a little number and 
proposed a small number of sample. As a consequence, it 
needs more study that compared both of therapy directly 
to get the more adequate conclusion.
Besides of its minimal study conducted, entecavir 
use in this case also facing a problem. Although both 
entecavir and lamivudine were found in Indonesia, 
entecavir were slightly more expensive in price and not 
¿QDQFHGE\QDWLRQDOKHDOWKLQVXUDQFH7KHUHVKRXOGEH
a study about cost-effectiveness between lamivudine 
and entecavir for HBV prevention. So, it can be 
concluded that lamivudine still the drug of choice for 
HBV reactivation prophylaxis until chemotherapy end 
in this case. Based on various guidelines, lamivudine 
in this case will be continued to the next six months 
DIWHUFKHPRWKHUDS\¿QLVKHG
CONCLUSION
From both of the study, it can be concluded 
that entecavir were more effective than lamivudine 
in positive HBsAg patients or in advanced stage 
malignancy patients undergo chemotherapy. Since 
entecavir cost was unaffordable, lamivudine still be a 
drug of choice in this case. 
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